

APPENDIX & EXHIBIT INDEX

Appendix	Description
A	Defamatory Statements on Social Media

Ex. No.	Date	Description
1	10/17/2022	Tweets by @Adrian_H re CUNY public hearing (https://twitter.com/Adrian_H/status/1582125936635392000), including images of “Statement to CUNY Manhattan Public Borough Hearing”
2	10/21/2022	Letters to the Board of Trustees Re: “Manhattan Borough Hearing and Public Hearing”
3	8/18/2021	Citizen’s Petition by Jordan A. Thomas, Partner at Labaton Sucharow LLP, including Citizen Petition Letter, Citizen Petition Report, and Dunn Letter
4	8/30/2021	Supplement to Citizen’s Petition by Jordan A. Thomas, Partner at Labaton Sucharow LLP
5	9/9/2021	Second Supplemental Statement of Concern by Jordan A. Thomas, Partner at Labaton Sucharow LLP (Docket #: FDA-2021-P-0930)
6	11/2/2021	Letter by Enea Milioris, Adrian Heilbut, Jesse Brodtkin, Patrick Markey to FDA
7	11/3/2021	Presentation: “Cassava Sciences: A Shambolic Charade” by Enea Milioris, Adrian Heilbut, Jesse Brodtkin, Patrick Markey
8	11/3/2021	Quintessential Capital Management Report: “Cassava Sciences (SAVA): Game over! A warning for the US healthcare system”
9	11/17/2021	Third Supplement to Citizen’s Petition by Jordan A. Thomas, Partner at Labaton Sucharow LLP
10	11/29/2021	Report: “SavaDx Exposed – A revolutionary diagnostic for Alzheimer’s Disease or a scam of scientifically illiterate investors?” by Jesse Brodtkin, Enea Milioris, Adrian Heilbut, Patrick Markey

Ex. No.	Date	Description
11	12/8/2021	Fourth Supplement to Citizen's Petition by Jordan A. Thomas, Partner at Labaton Sucharow LLP
12	12/10/2021	Report: "Cassava and the Wang Lab: Seeing Through the Blind" by Jesse Brodtkin, Enea Milioris, Adrian Heilbut, Patrick Markey
13	8/26/2021	Press Release by Labaton Sucharow: "Rebuttal to 8/25/2021 Cassava Sciences Press Release"
14	3/20/2022	Interview titled "Idea Brunch with Gabriel Grego of Quintessential Capital Management"
15	2/10/2022	FDA response to Jordan A. Thomas re Citizen's Petition
16	11/4/2021	Press Release: "Review by Journal of Neuroscience Shows No Evidence of Data Manipulation in Technical Paper Foundational to Cassava Sciences' Lead Drug Candidate"
17	12/21/2021	Press Release: "Science Journal Finds No Evidence to Support Claims of Data Manipulation in 2005 Publication"
18	8/18/2022	Press Release: "No Evidence of Data Manipulation in Science Publication on Simufilam"
19	6/15/2022	<i>Molecular Neurodegeneration</i> : "Calcium-dependent cytosolic phospholipase A2 activation is implicated in neuroinflammation and oxidative stress associated with ApoE4"
20	2/28/2022	US SEC Form 10-K Annual Report for Fiscal Year Ended December 31, 2021
21	3/23/2021	US SEC Form 10-K Annual Report for Fiscal Year Ended December 31, 2020
22	3/26/2020	US SEC Form 10-K Annual Report for Fiscal Year Ended December 31, 2019
23	3/27/2019	Press Release: "Pain Therapeutics Announces Name Change to Cassava Sciences, Inc."
24	4/15/2019	Press Release: "Cassava Sciences Completes Patient Enrollment for a Phase 2a Study in Patients with Alzheimer's Disease"
25	6/18/2019	Press Release: "Cassava Sciences to Present at Maxim Group's Conference on Alzheimer's Disease"

Ex. No.	Date	Description
26	9/9/2019	Press Release: “Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimer’s Patients”
27	9/16/2019	Press Release: “Cassava Sciences Initiates Phase 2b Clinical Study in Alzheimer’s Patients”
28	10/24/2019	Press Release: “Cassava Sciences’ Clinical Results in Alzheimer’s Selected as Late-Breaking News at CTAD 2019”
29	10/29/2019	Press Release: “Cassava Sciences Announces Recent Clinical Highlights and Third Quarter 2019 Financial Results”
30	12/6/2019	Press Release: “Cassava Sciences Announces Additional Positive Phase 2a Clinical Data in Alzheimer’s Disease at CTAD 2019”
31	1/28/2020	Press Release: “Cassava Sciences Announces Completion of Patient Enrollment of a Phase 2b Study in Alzheimer’s Disease”
32	2/11/2020	Press Release: “Cassava Sciences Announces Phase 2a Study of PTI-125 Published in The Journal of Prevention of Alzheimer’s Disease (JPAD)”
33	3/19/2020	Press Release: “Cassava Sciences Announces Clinical Update and Business Progress Across Neuroscience Pipeline”
34	3/25/2020	Press Release: “Cassava Sciences Announces Initiation of an Open-Label Study to Evaluate PTI-125 in Patients with Alzheimer’s Disease”
35	3/26/2020	Press Release: “Cassava Sciences Announces Full-year 2019 Financial Results and Anticipated Key Milestones for 2020”
36	4/23/2020	Press Release: “Cassava Sciences Announces New \$2.5 Million Research Grant Award from National Institutes of Health”
37	6/3/2020	Press Release: “Cassava Sciences Announces Presentation at the Jefferies Virtual Healthcare Conference and Provides Updates Regarding Phase 2b Study of PTI-125”
38	7/9/2020	Press Release: “Cassava Sciences to Give Keynote Presentation on SavaDx at a Scientific Conference”
39	8/12/2020	Press Release: “Cassava Sciences Announces Second Quarter 2020 Financial Results and Mid-year Business Review”

Ex. No.	Date	Description
40	9/14/2020	Press Release: “Cassava Sciences Announces Final Results of a Phase 2b Clinical Study of Simufilam in Patients with Alzheimer’s Disease”
41	9/30/2020	Press Release: “Cassava Sciences’ Phase 2b Clinical Results in Alzheimer’s Selected as Late-Breaking News at CTAD 2020”
42	11/4/2020	Press Release: “Cassava Sciences Announces Additional Clinical Data from a Phase 2b Study of Sumifilam in Alzheimer’s Disease”
43	1/4/2021	Press Release: “Cassava Sciences Appoints Dr. James Kupiec as Chief Clinical Development Officer”
44	2/2/2021	Press Release: “Cassava Sciences’ Simufilam Improves Cognition and Behavior in Alzheimer’s Disease in Interim Analysis of Open-label Study”
45	2/8/2021	Press Release: “Cassava Sciences Announces Significant Program Progress and Expected Key Milestones in 2021 for Its Clinical Program in Alzheimer’s Disease”
46	2/22/2021	Press Release: “Cassava Sciences Announces Positive End-of-Phase 2 Meeting with FDA and Outlines Pivotal Phase 3 Program for Simufilam in Alzheimer’s Disease”
47	2/23/2021	Press Release: “Cassava Sciences to Present at SVB Leerink Global Healthcare Conference”
48	3/23/2021	Press Release: “Cassava Sciences Announces Full-year 2020 Financial Results and Business Highlights”
49	4/21/2021	Press Release: “Cassava Sciences Reports First Quarter 2021 Financial Results and Announces Guidance on Clinical Data Release”
50	4/26/2021	Press Release: “Cassava Sciences Invited by the NIH to Participate in Sachs 4th Annual Neuroscience Innovation Forum”
51	4/27/2021	Press Release: “Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference”
52	5/10/2021	Press Release: “Cassava Sciences Announces Initiation of Cognition Maintenance Study in Alzheimer’s disease”

Ex. No.	Date	Description
53	5/12/2021	Press Release: “Cassava Sciences Announces New \$2.7 Million Research Grant Award from National Institutes of Health”
54	5/24/2021	Press Release: “Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimer’s Disease”
55	6/17/2021	Press Release: “Cassava Sciences to Present at the Raymond James 2021 Human Health Innovation Conference”
56	6/21/2021	Press Release: “Cassava Sciences Provides Mid-Year Corporate Update, Clinical Development Progress and Announces Guidance on Clinical Data Release”
57	6/21/2021	Press Release: “Cassava Sciences Selects Clinical Research Organization for Phase 3 Clinical Program in Alzheimer’s Disease”
58	7/21/2021	Press Release: “Cassava Sciences to Present New Clinical Dataset at 2021 Alzheimer’s Association International Conference”
59	7/26/2021	Press Release: “Cassava Sciences Announces Positive Data with SavaDx from a Randomized Controlled Phase 2b Study of Simufilam”
60	7/29/2021	Press Release: “Cassava Sciences Announces Positive Cognition Data With Simufilam in Alzheimer’s Disease”
61	7/29/2021	Press Release: “Cassava Sciences Announces Positive Biomarker Data with Simufilam in Alzheimer’s Disease”
62	8/24/2021	Press Release: “Cassava Sciences Announces Agreement with FDA on Special Protocol Assessments (SPA) for its Phase 3 Studies of Simufilam for the Treatment of Alzheimer’s Disease”
63	8/25/2021	Press Release: “Cassava Sciences Responds to Allegations”
64	8/27/2021	Press Release: “Cassava Sciences Releases Statement Regarding Plasma p-tau Analysis from a Previously Disclosed Phase 2b Clinical Study in Alzheimer’s Patients”
65	9/3/2021	Press Release: “Cassava Sciences Releases a Public Statement Regarding Recent Allegations”

Ex. No.	Date	Description
66	9/22/2021	Press Release: “Cassava Sciences Announces Top-line Results of 12-month Interim Analysis from Open-label Study Evaluating Simufilam in Alzheimer’s Disease”
67	10/6/2021	Press Release: “Cassava Sciences Initiates a Phase 3 Efficacy Trial of Simufilam for the Treatment of Patients with Alzheimer’s Disease”
68	11/18/2021	Press Release: “Cassava Sciences Initiates a Second Phase 3 Study of Simufilam for the Treatment of Patients with Alzheimer’s Disease”
69	12/23/2021	Press Release: “Cassava Sciences Launches Clinical Website to Support Phase 3 Studies of Oral Simufilam in Alzheimer’s Disease”
70	2/10/2022	Press Release: “FDA Denies Citizen Petitions Filed on Behalf of Short Selling Clients”
71	2/28/2022	Press Release: “Cassava Sciences Reports Full-year 2021 Financial Results and Operating Updates”
72	3/30/2022	Press Release: “Cassava Sciences Announces Fireside Chat and Presentation Tuesday, April 5th”
73	4/25/2022	Press Release: “Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference”
74	5/5/2022	Press Release: “Cassava Sciences Reports First Quarter Financial Results for 2022 and Updates on Phase 3 Clinical Program”
75	8/3/2022	Press Release: “Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study”
76	10/13/2022	Press Release: “Cassava Sciences Announces Initiation of an Open-label Extension Study”
77	11/4/2020	<i>Journal of Prevention of Alzheimer’s Disease</i> 7(4): “PTI-125 Reduces Biomarkers of Alzheimer’s Disease in Patients”
78	12/8/2017	<i>Neuroimmunology and Neuroinflammation</i> (December 2017): “Altered filamin A enables amyloid beta-induced tau hyperphosphorylation and neuroinflammation in Alzheimer’s disease Topic: Alzheimer’s Disease”

Ex. No.	Date	Description
79	3/31/2017	<i>Neurobiology of Aging</i> (2017): “PTI-125 binds and reverses an altered conformation of filamin A to reduce Alzheimer’s disease pathogenesis”
80	7/18/2012	<i>The Journal of Neuroscience</i> 32(29): “Reducing Amyloid-Related Alzheimer’s Disease Pathogenesis by a Small Molecule Targeting Filamin A”
81	2/1/1998	<i>The Journal of Neuroscience</i> 18(3): “Interaction of Presenilins with the Filamin Family of Actin-Binding Proteins”
82	7/11/2000	<i>Neuro Report</i> 11(14): “Presenilin 1 interaction with cytoskeleton and association with actin filaments”
83	9/13/2000	<i>Journal of Cell Science</i> 113: “Physical and genetic interaction of filamin with presenilin in <i>Drosophila</i> ”
84	11/1/2004	<i>Nature Cell Biology</i> December (2004): “The many faces of filamin: A versatile molecular scaffold for cell motility and signalling”
85	02/1/2009	<i>Journal of Neuropathology & Experimental Neurology</i> 68(2): “Hyaline Protoplasmic Astrocytopathy of Neocortex”
86	6/11/2010	<i>Journal of Alzheimer’s Disease</i> 22: “Alzheimer’s Disease Linked Presenilin Mutation (PS1M146L) Induces Filamin Expression and âSecretase Independent Redistribution”
87	8/28/2014	<i>Journal of Physiology – Paris</i> 108: “Participation of group I p21-activated kinases in neuroplasticity”
88	11/10/2005	<i>Acta Neuropathologica Communications</i> (2015): “Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLTDP brains”
89	6/28/2019	<i>Experimental Neurobiology</i> (2019): “Memantine Improves Cognitive Function and Alters Hippocampal and Cortical Proteome in Triple Transgenic Mouse Model of Alzheimer’s Disease”
90	2/19/2020	<i>Science Translational Medicine</i> (2020): “Filamin A inhibition reduces seizure activity in a mouse model of focal cortical malformations”
91	11/19/2020	<i>Frontiers in Cell and Developmental Biology</i> (2020): “Echinacoside Suppresses Amyloidogenesis and Modulates F-

Ex. No.	Date	Description
		actin Remodeling by Targeting the ER Stress Sensor PERK in a Mouse Model of Alzheimer's Disease"
92	5/10/2010	<i>Brain Research 1345 (2010)</i> : "Filamin-A and Myosin VI colocalize with fibrillary Tau protein in Alzheimer's disease and FTDP-17 brains"
93	11/17/2021	<i>Global Newswire</i> : "Protego Biopharma Raises \$51 Million Series A Financing to Advance the Treatment of Protein Misfolding Diseases"
94	7/7/1994	<i>Biochem Journal (1994)</i> : "[³ H]PtdIns hydrolysis in postmortem human brain membranes is mediated by the G-proteins G _{q/11} and phospholipase C-β"
95	7/9/1996	<i>Neurobiology of Aging (1997)</i> : "Cholinergic Activation of Phosphoinositide Signaling Is Impaired in Alzheimer's Disease Brain"
96	1/1/2002	<i>The FASEB Journal (January 2002)</i> : "Cells in human postmortem brain tissue slices remain alive for several weeks in culture"
97	7/2004	<i>Archives of General Psychiatry Vol 61 (July 2004)</i> : "Decreased Catalytic Activity and Expression of Protein Kinase C Isozymes in Teenage Suicide Victims"
98	9/27/2004	<i>The American Journal of Human Genetics (2004)</i> : "Functional Analysis of Genetic Variation in Catechol-O-Methyltransferase (COMT): Effects on mRNA, Protein, and Enzyme Activity in Postmortem Human Brain"
99	12/12/2007	<i>Neuropsychopharmacology (2008)</i> : "Lower Phosphoinositide 3-Kinase (PI 3-kinase) Activity and Differential Expression Levels of Selective Catalytic and Regulatory PI 3-Kinase Subunit Isoforms in Prefrontal Cortex and Hippocampus of Suicide Subjects"
100	2/16/2012	<i>Neuro-degenerative Diseases (2012)</i> : "Protein Kinase Activity Profiling of Postmortem Human Brain Tissue"
101	7/1/2011	<i>Archives of General Psychiatry (July 2011)</i> : "Downregulated Kynurenine 3-Monooxygenase Gene Expression and Enzyme Activity in Schizophrenia and Genetic Association With Schizophrenia Endophenotypes"

Ex. No.	Date	Description
102	3/20/2014	<i>Neurobiology of Aging (2014)</i> : “Altered arginine metabolism in Alzheimer’s disease brains”
103	5/1/2015	<i>Journal of Nuclear Medicine (May 2015)</i> : “Glutamate-induced Hyperactivity of NMDA ion channel in Postmortem Alzheimer’s Disease Brains”
104	9/3/2021	Transcript of Public Statement Regarding Recent Allegations Against Cassava Sciences, Inc.
105	10/21/2021	Blog Post from ad-science.org titled “Notes from a Molecular Biologist”
106	10/21/2021	Blog Post from ad-science.org titled “Of Shorts and Blots”